Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27924495 | 0.94 | TSHR (0.36) | TSHRTP53SLC7A5MMP1MMP2 | |
| SCHEMBL866513 | 0.78 | TSHR (0.38) | TSHRTP53SLC7A5MMP1MMP2 | |
| SCHEMBL19359798 | 0.75 | — | — | |
| SCHEMBL222174 | 0.75 | — | — | |
| SCHEMBL5377017 | 0.75 | TSHR (0.58) | TSHRCTSKSMN1; SMN2 | |
| SCHEMBL1936262 | 0.73 | TSHR (0.40) | TSHRTP53SLC7A5MMP1MMP2 | |
| SCHEMBL4367765 | 0.73 | TSHR (0.40) | TSHRTP53SLC7A5MMP1MMP2 | |
| SCHEMBL36671 | 0.73 | — | — | |
| SCHEMBL3262366 | 0.73 | LMNA (0.44) | TSHRSLC7A5HCAR2CTSK | |
| Ammonia Solution, Strong SCHEMBL2277693 | 0.73 | TSHR (0.35) | TSHRTP53SLC7A5MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| JP-1100176-A | — | — | None | — | — | JP | disclosed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| US-11773219-B2 | Functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-09-14 | — | — | US | disclosed |
| US-11723981-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-08-15 | — | — | US | disclosed |
| US-20230022913-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2023-01-26 | — | — | US | disclosed |
| US-11510989-B2 | Conjugates of biologically active molecules to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-11-29 | — | — | US | disclosed |
| US-11382984-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-07-12 | — | — | US | disclosed |
| EP-1289999-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2003-03-12 | — | — | EP | disclosed |
| EP-1287004-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF AN ECTEINASCIDIN COMPOUND | PHARMA MAR, S.A. (ES) | 2003-03-05 | — | — | EP | disclosed |
| EP-1280809-A1 | ANTITUMORAL ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2003-02-05 | — | — | EP | disclosed |
| EP-1185536-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001087894-A1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR, S.A. (ES) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087895-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF AN ECTEINASCHIDIN COMPOUND | PHARMA MAR, S.A. (ES) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001077115-A1 | ANTITUMORAL ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2001-10-18 | — | — | WO | disclosed |
| WO-2000069862-A2 | HEMISYNTHETIC METHOD AND INTERMEDIATES THEREOF | PHARMA MAR, S.A. (ES) | 2000-11-23 | — | — | WO | disclosed |
| JP-H01100176-A | NOVEL BICYCLIC COMPOUND | TOUBISHI YAKUHIN KOGYO KK | 1989-04-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285574-A1 | CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS | CD44, EPCAM, ALG1 | TSHR 2212/4885TP53 135/4885SLC7A5 1883/4885 |
| US-20230022913-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | TSHR 1780/4885TP53 22/4885SLC7A5 2218/4885 |
| US-11723981-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | TNF, TNFRSF1A, TNFSF11 | TSHR 1780/4885TP53 22/4885SLC7A5 2218/4885 |
| US-11773219-B2 | Functionalized polymers | PARG, PUF60, PCBP1 | TSHR 3799/4885TP53 329/4885SLC7A5 2430/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | TSHR 1780/4885TP53 22/4885SLC7A5 2218/4885 |
| US-11510989-B2 | Conjugates of biologically active molecules to functionalized polymers | CD44, EPCAM, ALG1 | TSHR 2212/4885TP53 135/4885SLC7A5 1883/4885 |
| US-11382984-B2 | Conjugates of tumor necrosis factor inhibitors to functionalized polymers | TNF, TNFRSF1A, TNFSF11 | TSHR 1780/4885TP53 22/4885SLC7A5 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.